6 recruiting, 2 completed. 4 Phase 3, 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Recruiting 4 |
| Phase 2 | 3 | Recruiting 2, Completed 1 |
| Phase 1 | 1 | Completed 1 |
Follow PCV 20: new trials by email Literature Review of PCV 20 trials Research Report on PCV 20
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age Investigational varicella vaccine, Marketed varicella vaccine, MMR vaccine - Chickenpox | Phase 3 | Recruiting | GlaxoSmithKline | 600 | 2025-05-15 | 2026-05-29 |
| A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age Candidate varicella vaccine, Marketed varicella vaccine, MMR vaccine - Chickenpox | Phase 3 | Recruiting | GlaxoSmithKline | 911 | 2025-04-17 | 2026-05-29 |
| A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age Investigational varicella vaccine_Lot 1, Investigational varicella vaccine_Lot 2, Investigational varicella vaccine_Lot 3 - Chickenpox | Phase 3 | Recruiting | GlaxoSmithKline | 1840 | 2025-01-10 | 2026-05-29 |
| A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age Investigational varicella vaccine, Marketed varicella vaccine, Measles, mumps, and rubella vaccine - Chickenpox | Phase 3 | Recruiting | GlaxoSmithKline | 750 | 2024-11-26 | 2026-05-29 |
| Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine IVT PCV-25 Formulation A, IVT PCV-25 Formulation B, IVT PCV-25 Formulation C - Pneumococcal Vaccines | Phase 2 | Completed | Inventprise Inc. | 220 | 2023-10-25 | 2026-03-17 |
| Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia Pneumococcal 20-valent Conjugate Vaccine, Pneumococcal Polyvalent Vaccine - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Seema Bhat | 80 | 2023-09-29 | 2026-01-07 |
| Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine IVT PCV-25, PCV 20 - Pneumococcal Vaccines | Phase 1 | Completed | Inventprise Inc. | 65 | 2022-09-28 | 2023-08-30 |
| Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial Pneumococcal 20-valent Conjugate Vaccine, Pneumococcal Polyvalent Vaccine - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | University of Utah | 61 | 2022-01-31 | 2026-04-09 |
Chickenpox (4) · Leukemia, Lymphocytic, Chronic, B-Cell (2)
GlaxoSmithKline (4) · Inventprise Inc. (2) · Seema Bhat (1) · University of Utah (1)
United States (5) · Estonia (3) · Poland (3) · Belgium (2) · Canada (2) · Dominican Republic (2) · Mexico (2) · Thailand (2) · Bulgaria (1) · Colombia (1) · Czechia (1) · Denmark (1) · Greece (1) · Honduras (1) · Hong Kong (1)
Daniel Ermann, MD (1) · Joanne Langley, MD, MSc, FRCPC (1) · Seema A Bhat, MD (1) · Sybil Tasker, MD, MPH, FIDSA (1)